Saturday, May 26, 2007
A Healthy Perspective on Cancer Treatment
Alternative cancer treatment facility in Mesa AZ, An Oasis of Healing, launches AnOasisOfHealing.com. Thomas Lodi, MD, Homeopathic Physician and owner of An Oasis of Healing, explains the fundamental steps needed to take to naturally heal cancer.
Mesa, AZ (PRWEB) May 26, 2007 -- Thomas Lodi, MD, Homeopathic Physician and owner of An Oasis of Healing, Integrative Oncology Cancer Treatment facility in Mesa, Arizona, has just launched his new website AnOasisOfHealing.com, which provides options for alternative cancer treatment.
AnOasisofHealing.com provides you with information about the three fundamental aspects employed to treat cancer: (1) Teaching the patient to stop making cancer (2) Selectively targeting and destroying cancer without harming the person (3) Stimulating and enhancing the immune system.
Dr. Thomas Lodi also encourages those seeking a more integrative and alternative method of cancer treatment to contact the center through the website AnOasisOfHealing.com. The facility is located in downtown Mesa, Arizona and the website will provide you with further information on how to set up an appointment, what to expect during your first visit, travel information, and directions.
Press Contact: Clothilde Canale
Company Name: An Oasis of Healing
Phone: (480) 834-5414
Friday, May 25, 2007
Comprehensive Mesothelioma Glossary
LegalView.com, your resource for everything legal, has introduced a new glossary of terminology relating to the condition mesothelioma located at http://mesothelioma.legalview.com/glossary.
(PRWEB) May 25, 2007 -- LegalView.com, your resource for everything legal, has introduced a new glossary of terminology relating to the condition mesothelioma. This terminology reference is intended to add to LegalView.com's full range of Mesothelioma resources. The glossary features hundreds of legal and medical terms and exists as a compliment to the site's articles and legal information related to mesothelioma.
The glossary, located at http://mesothelioma.legalview.com/glossary, adds to the already exhaustive resources related to mesothelioma located at LegalView.com. The glossary contains hundreds of terms and acts a companion piece to the full spectrum of mesothelioma related legal resources contained on LegalView.com's mesothelioma portal, which include articles, a mesothelioma blog, and various other bits of helpful mesothelioma legal information, as well as links providing access to mesothelioma legal advice.
Mesothelioma is a rare but fatally serious form of lung cancer that is nearly always connected to asbestos exposure. LegalView.com created its mesothelioma information portal as a free service for those looking for the latest news and information about mesothelioma and its effects, especially for mesothelioma patients and their families. This comprehensive glossary compliments the full range of articles and wide selection of links relating to mesothelioma lawsuits and mesothelioma claims, adding depth and value to the site's other legal resources. In addition to these mesothelioma legal resources, LegalView.com features a legal encyclopedia and links to helpful legal websites in each state.
LegalView.com stands on the cutting edge of approachable and useful legal content, and its new mesothelioma glossary is certainly no exception. Have questions about other legal matters? In addition to upcoming collections of legal resources related to auto accidents and practice areas for birth injuries and child injuries, LegalView.com also features extensive information on other legal issues such as automobile accidents, medical malpractice, occupational diseases and securities fraud. In addition, its attorney referral system allows parties looking for legal representation to get in touch with experienced lawyers quickly.
LegalView.com is a free public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz' Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez Hodes; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.legalview.com.
Press Contact: Peter Kent
Company Name: LegalView.com
Monday, May 21, 2007
Advanced Technology Now Found At Cancer Center
NomosSTAT Encore Serial Tomotherapy System in use for 6 months at NY Cancer Center.
Rochester, NY (PRWEB) May 21, 2007 -- Dr. Charles H. Albrecht, director of Finger Lakes Radiation Oncology Center in Clifton Springs, NY announced today that the center has been using the nomosSTAT Encore Serial Tomotherapy System for 6 months. "This equipment allows us to use Intensity Modulated Radiation Therapy (IMRT) in patients with a wider variety of diseases. We have seen great improvement in side effects during treatment of pelvic malignancies and expect that these patients will have fewer long-term complications." IMRT makes it possible to precisely treat cancers which are surrounded by structures which must be protected, so that higher doses of radiation can be delivered with fewer side effects and complications. Nomos (North American Scientific) pioneered IMRT technology in the 1990s, and in 2000 Finger Lakes Radiation Oncology was the first center in the area to install the original Nomos system. The center started treating patients with the new equipment in November, 2006.
About The Finger Lakes Radiation Oncology Center
Finger Lakes Radiation Oncology Center (FLROC), founded in 1985 by Dr. Sidney Sobel, provides a radiation treatment center for patients in the Finger Lakes area. The FLROC is attached to both the Clifton Springs Hospital & Clinic (CSH&C) and The Springs, allowing our patients convenient access to additional services and providers. FLROC has technology comparable and in some cases better than technology available in large centers and our treatment planning is more sophisticated and elegant than is common elsewhere. We also offer brachytherapy services including prostate seed implants, gynecologic implants, and Iodine therapy for thyroid cancer and hyperthyroidism. Please Visit our Web site at: www.flrocenter.com.
Press Contact: Dr. Charles H. Albrecht, M.D.
Company Name: Finger Lakes Radiation Oncology Center
Phone: (315) 462-5711
Sunday, May 20, 2007
Deaths From Asbestos-Related Mesothelioma Continue to Rise
FFW support the latest figures from the British Mesothelioma Register which show that deaths caused by mesothelioma, caused by exposure to asbestos, continues to rise
(PRWEB) May 20, 2007 -- Evidence from Field Fisher Waterhouse supports the latest figures from the latest figures from the British Mesothelioma Register which shows that deaths caused by mesothelioma, a cancer of the lining of the lungs caused by exposure to asbestos, is continuing to rise.
The Asbestos Claims (http://www.ffw.com/Areas-Of-Expertise/Personal-Injury/Asbestos-Compensation.aspx ) Department at law firm, Field Fisher Waterhouse LLP, has been recovering compensation for victims of mesothelioma for 25 years. The statistics confirm the rise that the team's lawyers have seen reflected in their caseload over the years.
The figures show that the number of deaths caused by mesothelioma have risen from 153 in 1968, to 1969 deaths in 2004, with the majority of deaths occurring in men. The figures suggest that the peak in mesothelioma mortality in this country may occur in the next few years.
The figures show that the geographical areas associated with the highest mesothelioma (http://www.ffw.com/Areas-Of-Expertise/Personal-Injury/Asbestos-Compensation/what-is-asbestos.aspx ) mortality are those associated with industries which in the past were responsible for high levels of exposure to asbestos.
Andrew Morgan, partner in the Asbestos Compensation (http://www.ffw.com/Areas-Of-Expertise/Personal-Injury/Asbestos-Compensation.aspx ) Claims Department at Field Fisher Waterhouse, said:
"These national figures confirm our experience that mesothelioma deaths are continuing to rise. They show that we have not yet reached the peak in mesothelioma mortality. Since Field Fisher Waterhouse began working on these cases 25 years ago we have seen cases increase from around 200 a year to figures in the region of 2000 a year. Whilst these figures may not increase much over the next few years they will not fall to low levels again for perhaps 20 years or more."
Those most commonly affected by asbestos diseases include individuals who worked with asbestos-containing materials, such as laggers, pipe-fitters and carpenters, however over the years Andrew and the Asbestos Compensation Claims (http://www.ffw.com/Areas-Of-Expertise/Personal-Injury/Asbestos-Compensation.aspx ) Department have seen a significant increase in the number of claims from people who were exposed secondarily to asbestos. This includes those whose relatives brought home asbestos on contaminated overalls or who were not in direct contact with asbestos themselves but worked alongside colleagues who did have direct contact with the substance. In addition, Field Fisher Waterhouse has acted on behalf of varied professionals such as doctors, nurses and teachers who in turn developed mesothelioma after having been exposed to asbestos at work.
Last year alone the Asbestos Claims Department recovered over £10 million in compensation for victims in 87 successful cases. Since the Department was set up, the firm has recovered over £106 million in more than 1800 successful asbestos claims.
For further information please contact:
Andrew Morgan (andrew.morgan(at)ffw.com)
Asbestos Claims Department
Field Fisher Waterhouse LLP
35 Vine Street
020 7861 4036
Press Contact: Andrew Morgan
Company Name: Field Fisher Waterhouse LLP Phone: 020 7861 4036
Saturday, May 12, 2007
Mesothelioma-Search-Engine.com - Onconase as Chemopreventive Agent in Mesothelioma
Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ -- ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate, may have potential as a chemopreventive agent, according to world-renowned mesothelioma researcher Michele Carbone M.D., Ph.D., at this week's American Association for Cancer Research (AACR) Annual Meeting.
In a series of poster presentations, Dr. Carbone highlighted the growing worldwide problem of asbestos exposure and its link to malignant mesothelioma. Dr. Carbone presented data that show the early detection in patients at high risk for developing malignant mesothelioma is becoming more prevalent via the presence of certain biological markers in blood samples. Furthermore, he pointed out that ONCONASE's favorable toxicity profile and its well-documented mechanism of action, which directly affects the pathway that has been shown to cause asbestos carcinogenesis, position ONCONASE for potential early administration to populations "at-risk" for mesothelioma. If clinically validated, such a new approach might enable physicians to use ONCONASE as a chemopreventive agent to potentially prevent the onset of mesothelioma, or reduce the doses of cytotoxic agents needed in those patients who develop the disease.
"The potential of ONCONASE as an early first-line preventative treatment for mesothelioma is an exciting development that we plan to investigate through clinical trials," said Dr. Carbone. "With approximately more than 25 million asbestos exposure cases reported worldwide, we believe that ONCONASE might play a greater role in the treatment protocols for a much larger population than was originally envisioned for this dismal disease."
Dr. Carbone is a professor and director of the thoracic oncology program as well as a clinical professor of pathology with the University of Hawaii's Cancer Research Center of Hawaii, and chairman of the Alfacell Thoracic Advisory Board. Previously, Dr. Carbone was Director of the Thoracic Oncology Program at Loyola University in Chicago, where he is also a tenured Professor at the Cancer Center, Department of Pathology. He also held scientific and academic positions at the National Institutes of Health (NIH), and at the University of Chicago.
Kuslima Shogen, Alfacell's chairman and chief executive officer, added: "Dr. Carbone is recognized as one of the world's leading researchers in mesothelioma. His remarks about ONCONASE at the AACR Annual Meeting reflect the interest of the international medical community in expanding the potential uses of ONCONASE."
ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Media Contact: Investor Contact:
David Schull or Wendy Lau Andreas Marathovouniotis
Noonan Russo Noonan Russo
firstname.lastname@example.org email@example.com firstname.lastname@example.org
CONTACT: David Schull or Wendy Lau, +1-212-845-4271, or, or , or AndreasMarathovouniotis, +1-212-845-4253, or , all ofNoonan Russo email@example.com firstname.lastname@example.org email@example.com
Web site: http://www.alfacell.com/http://www.noonanrusso.com/
Wednesday, May 09, 2007
Find a Lawyer at Lawyer Referral Directory
The fastest way to find a lawyer online is now freely available to the public.
Kings Park, NY (PRWEB) May 9, 2007 - The American Lawyer Referral Directory has gone live at http://www.americanlawyerreferral.com. This new Web site offers users a fast, free and easy way to find a lawyer -- without having to reveal any personal information.
In response to growing privacy concerns, the American Lawyer Referral online legal directory permits users to browse anonymously for lawyers without having to pay fees, register, complete forms or reveal their e-mail address. Lawyers are categorized by state, county and practice type in more than 400,000 "white pages" style directory listings.
Utilizing Microsoft's ASP.NET technology, AJAX programming, an MS SQL database and encompassing more than 50,000 dynamic pages, the American Lawyer Referral Directory was designed with speed and ease of use as primary considerations. The site is free of extraneous distractions, animated banners and pop-up ads. From the home page users may quickly locate lawyers by practice type in any U.S. county and state -- using only three clicks.
Additional considerations in the development of the site included search engine optimization (SEO) features such as a proprietary system of generating search-engine-friendly file names as well as unique title and header tags for each page. These enhancements allow Google, Yahoo!, MSN, Ask and other search engines to crawl the site unimpeded and accurately index its extensive lawyer listings.
So whether you require a personal injury lawyer in Los Angeles, CA; a divorce lawyer in New York, NY; or a criminal defense lawyer in Miami, FL -- the American Lawyer Referral Directory is a fast, free and easy way to begin and end your search for legal services.
In addition to providing free information to the public, the American Lawyer Referral Directory offers free and paid advertising opportunities to qualified attorneys. Please visit http://www.americanlawyerreferral.com/free-advertising-for-your-law-firm.aspx for additional details.
# + ##
Press Contact: A.M. D'Elia
Company Name: American Lawyer Referral
Return to Mesothelioma Search Blog Home Page mesothelioma